Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9170494 | 1.00 | TRPA1 (0.59) | TRPA1MAOAMAOBPTGS1PTGS2 | |
| Ammonia Solution, Strong SCHEMBL349727 | 0.97 | TRPA1 (0.57) | TRPA1MAOAMAOBPTGS1PTGS2 | |
| SCHEMBL13017113 | 0.93 | TRPA1 (0.53) | TRPA1MAOAMAOBPTGS1PTGS2 | |
| SCHEMBL24244793 | 0.93 | TRPA1 (0.53) | TRPA1MAOAMAOBPTGS1PTGS2 | |
| SCHEMBL8056212 | 0.87 | TRPA1 (0.48) | TRPA1MAOAMAOB | |
| SCHEMBL1131597 | 0.86 | PTGS1 (0.56) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL24827555 | 0.84 | TRPA1 (0.50) | TRPA1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL5174938 | 0.83 | PTGS1 (0.54) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL18391826 | 0.82 | TRPA1 (0.44) | TRPA1MAOAMAOBHTR2ALOXL2 | |
| Hydrogen Peroxide SCHEMBL9581174 | 0.80 | PTGS1 (0.64) | PTGS1PTGS2LMNACYP2C9AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 742 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928134-B2 | 5-aryl-4,5-dihydro-(1H)-pyrazolines as cannabinoid CB1 receptor agonists | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-04-19 | — | — | US | claimed |
| WO-2010131147-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | claimed |
| WO-2010131146-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | claimed |
| WO-2010131145-A1 | CYCLOBUTENEDIONE DERIVATIVES | PFIZER LIMITED (GB) | 2010-11-18 | — | — | WO | claimed |
| CN-101801934-A | 5-aryl-4, 5-dihydro- (1H) -pyrazoles as cannabis sativaPlain CB1Receptor agonists | SOLVAY PHARM BV | 2010-08-11 | — | — | CN | claimed |
| EP-2203427-A2 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS | Abbott Healthcare Products B.V. (NL) | 2010-07-07 | — | — | EP | claimed |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. | 2009-03-26 | — | — | US | claimed |
| WO-2009037244-A2 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-03-26 | — | — | WO | claimed |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | claimed |
| US-20070249639-A1 | Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives | BAENTELI ROLF | 2007-10-25 | — | — | US | claimed |
| EP-1844002-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | claimed |
| EP-1832586-A1 | Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas | Oridis Biomed Forschungs- und Entwicklungs GmbH (AT) | 2007-09-12 | — | — | EP | claimed |
| EP-1734968-A2 | USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES | Novartis AG (CH) | 2006-12-27 | — | — | EP | claimed |
| WO-2006083924-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| WO-2005097135-A2 | USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | claimed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | claimed |
| US-20240244961-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | TRPA1 694/4885MAOA 1463/4885MAOB 1393/4885 |
| US-20090082396-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | CNR1, CNR2, HTR5A | TRPA1 269/4885MAOA 1191/4885MAOB 1112/4885 |
| US-20240244961-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC APPARATUS | AOX1, AOC2, OSTC | TRPA1 99/4885MAOA 288/4885MAOB 353/4885 |
| US-20070249639-A1 | Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives | HPRT1, NUDT1, DPYD | TRPA1 4249/4885MAOA 1936/4885MAOB 756/4885 |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | REN, AGTR1, AGTR2 | TRPA1 1008/4885MAOA 533/4885MAOB 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.